In a report released yesterday, Matthew Lillis from Cantor Fitzgerald reiterated a Buy rating on Supernus Pharmaceuticals (SUPN – Research Report), with a price target of $57. The company’s shares closed yesterday at $35.95.
“: We reiterate our OW rating and 12-month $57 PT. We believe the next 6-12 months will be an important period for SUPN and investors as growth drivers begin to materialize. With the new monotherapy indication potentially accelerating Oxtellar XR growth, additional pipeline data readouts expected this year, and ample cash for BD, we believe these and other catalysts could drive investor enthusiasm and position the company well for the long term.”
According to TipRanks.com, Lillis is ranked #2638 out of 5144 analysts.
Supernus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $59.40.
Supernus Pharmaceuticals’ market cap is currently $1.88B and has a P/E ratio of 19.61. The company has a Price to Book ratio of 4.45.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.